Avoid common mistakes on your manuscript.
Article Corrected
Benedict Á, Verdian L, Maclaine G. The cost effectiveness of rufinamide in the treatment of Lennox-Gastaut syndrome in the UK. PharmacoEconomics 2010; 28 (3): 185–99
Correction Made
Page 194, column 2, final sentence of the Results section, which previously read:
“By contrast, the cost-effectiveness acceptability curve for the total seizure analysis shows rufinamide to be cost effective in 80% of analyses if society is willing to pay £900 for a 1% increase in the number of successfully treated patients (figure 2b).”
has now been corrected as follows:
“By contrast, the cost-effectiveness acceptability curve for the total seizure analysis shows that above £2150 rufinamide has the highest chance of being cost effective across the treatment comparisons (figure 2b).”
Note
All online versions of this article have been updated to reflect this correction.
Additional information
The original online version for this chapter can be found at http://dx.doi.org/10.2165/11313640-000000000-00000
Rights and permissions
About this article
Cite this article
Benedict, Á., Verdian, L. & Maclaine, G. Erratum to: The cost effectiveness of rufinamide in the treatment of Lennox-Gastaut syndrome in the UK. Pharmacoeconomics 29, 1014 (2011). https://doi.org/10.2165/11598620-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11598620-000000000-00000